1. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2
- Author
-
Scott W. Canna, Jessie L. Barnum, Darshit Thakrar, Corinne Schneider, Julia Segal, Steven William Allen, Miguel Reyes-Múgica, Jessica D Daley, Cláudia M. Salgado, and Serter Gumus
- Subjects
0301 basic medicine ,endocrine system ,medicine.medical_specialty ,Immunology ,Anti-Inflammatory Agents ,Salvage therapy ,Tachypnea ,Gastroenterology ,Article ,Dexamethasone ,Lymphohistiocytosis, Hemophagocytic ,03 medical and health sciences ,Fatal Outcome ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Immunologic Factors ,Immunology and Allergy ,Medicine ,Alemtuzumab ,Etoposide ,Inflammation ,Salvage Therapy ,Anakinra ,Hemophagocytic lymphohistiocytosis ,biology ,Perforin ,business.industry ,Perforin Deficiency ,fungi ,Antibodies, Monoclonal ,Immunoglobulins, Intravenous ,Infant ,Familial Hemophagocytic Lymphohistiocytosis ,musculoskeletal system ,medicine.disease ,Antibodies, Neutralizing ,Interleukin 1 Receptor Antagonist Protein ,030104 developmental biology ,biology.protein ,Female ,medicine.symptom ,business ,hormones, hormone substitutes, and hormone antagonists ,030215 immunology ,medicine.drug - Abstract
Familial hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome resulting from defective cytotoxicity. A previously healthy 3-month-old female presented with fever, irritability, abdominal distention, and tachypnea. She ultimately met all eight HLH-2004 diagnostic criteria, accompanied by elevated CXCL9. Initial empiric anti-inflammatory treatment included anakinra and IVIg, which stabilized ferritin and cytopenias. She had molecular and genetic confirmation of perforin deficiency and was started on dexamethasone and etoposide per HLH-94. She clinically improved, though CXCL9 and sIL-2Ra remained elevated. She was readmitted at week 8 for relapsed HLH without clear trigger and HLH-94 induction therapy was reinitiated. Her systemic HLH symptoms failed to respond and she soon developed symptomatic CNS HLH. She was incidentally found to have multifocal lung and kidney nodules, which were sterile and consisted largely of histiocytes and activated, oligoclonal CD8 T cells. The patient had a laboratory response to salvage therapy with alemtuzumab and emapalumab, but progressive neurologic decline led to withdrawal of care. This report highlights HLH foci manifest as pulmonary/renal nodules, demonstrates the utility of monitoring an array of HLH biomarkers, and suggests possible benefit of earlier salvage therapy.
- Published
- 2021
- Full Text
- View/download PDF